Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Rhythm · Phase 2 · Completed · Enrollment 213

NCT03013543

EudraCT 2017-000387-14

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
16p11.2 Cohortn/rn/rn/rn/r
AS Cohortn/rn/rn/rn/r
BBS Cohortn/rn/rn/rn/r
MC4R Cohortn/rn/rn/rn/r
POMC/PCSK1/LEPR Heterozygous Cohortn/rn/rn/rn/r
POMC/PCSK1/LEPR Composite Heterozygous Cohortn/rn/rn/rn/r
POMC/PCSK1/LEPR Compound Heterozygous Cohortn/rn/rn/rn/r
SH2B1 Cohortn/rn/rn/rn/r
SMS Cohortn/rn/rn/rn/r
SRC1 Cohortn/rn/rn/rn/r

Not shown

  • 16p11.2 Cohort: endpoint not reported
  • AS Cohort: endpoint not reported
  • BBS Cohort: endpoint not reported
  • MC4R Cohort: endpoint not reported
  • POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
  • POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
  • POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
  • SH2B1 Cohort: endpoint not reported
  • SMS Cohort: endpoint not reported
  • SRC1 Cohort: endpoint not reported